ID   UGPA_HUMAN              Reviewed;         508 AA.
AC   Q16851; Q07131; Q0P6K2; Q86Y81; Q9BU15;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 5.
DT   10-MAY-2017, entry version 154.
DE   RecName: Full=UTP--glucose-1-phosphate uridylyltransferase;
DE            EC=2.7.7.9;
DE   AltName: Full=UDP-glucose pyrophosphorylase;
DE            Short=UDPGP;
DE            Short=UGPase;
GN   Name=UGP2; Synonyms=UGP1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION, AND
RP   VARIANT ILE-268.
RC   TISSUE=Liver;
RX   PubMed=8354390; DOI=10.1016/0014-5793(93)80213-E;
RA   Peng H.-L., Chang H.-Y.;
RT   "Cloning of a human liver UDP-glucose pyrophosphorylase cDNA by
RT   complementation of the bacterial galU mutation.";
RL   FEBS Lett. 329:153-158(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT ILE-268.
RC   TISSUE=Skeletal muscle;
RX   PubMed=8631325; DOI=10.1111/j.1432-1033.1996.00173.x;
RA   Duggleby R.G., Chao Y.C., Huang J.G., Peng H.-L., Chang H.-Y.;
RT   "Sequence differences between human muscle and liver cDNAs for
RT   UDPglucose pyrophosphorylase and kinetic properties of the recombinant
RT   enzymes expressed in Escherichia coli.";
RL   Eur. J. Biochem. 235:173-179(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Cervix, Lymph, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   MUTAGENESIS.
RX   PubMed=8612650; DOI=10.1111/j.1432-1033.1996.t01-1-00723.x;
RA   Chang H.-Y., Peng H.-L., Chao Y.C., Duggleby R.G.;
RT   "The importance of conserved residues in human liver UDPglucose
RT   pyrophosphorylase.";
RL   Eur. J. Biochem. 236:723-728(1996).
RN   [5]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-438, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [6]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2 (ISOFORM 2),
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2 (ISOFORM 2), CLEAVAGE
RP   OF INITIATOR METHIONINE [LARGE SCALE ANALYSIS] (ISOFORM 2), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [8]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2 (ISOFORM 2),
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-13, PHOSPHORYLATION
RP   [LARGE SCALE ANALYSIS] AT SER-2 (ISOFORM 2), CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS] (ISOFORM 2), AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [9]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2 (ISOFORM 2), CLEAVAGE OF
RP   INITIATOR METHIONINE [LARGE SCALE ANALYSIS] (ISOFORM 2), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [10]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2 (ISOFORM 2), CLEAVAGE OF
RP   INITIATOR METHIONINE [LARGE SCALE ANALYSIS] (ISOFORM 2), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-13, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-13; THR-426; SER-434;
RP   SER-448 AND SER-461, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (3.57 ANGSTROMS), SUBUNIT, AND MUTAGENESIS OF
RP   502-ASP--LEU-503.
RX   PubMed=22132858; DOI=10.1042/BJ20111598;
RA   Yu Q., Zheng X.;
RT   "The crystal structure of human UDP-glucose pyrophosphorylase reveals
RT   a latch effect that influences enzymatic activity.";
RL   Biochem. J. 442:283-291(2012).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (3.35 ANGSTROMS) OF 2-508 IN COMPLEX WITH
RP   UDP-GLUCOSE.
RX   PubMed=25860585; DOI=10.1038/srep09618;
RA   Fuhring J.I., Cramer J.T., Schneider J., Baruch P., Gerardy-Schahn R.,
RA   Fedorov R.;
RT   "A quaternary mechanism enables the complex biological functions of
RT   octameric human UDP-glucose pyrophosphorylase, a key enzyme in cell
RT   metabolism.";
RL   Sci. Rep. 5:9618-9618(2015).
CC   -!- FUNCTION: Plays a central role as a glucosyl donor in cellular
CC       metabolic pathways.
CC   -!- CATALYTIC ACTIVITY: UTP + alpha-D-glucose 1-phosphate =
CC       diphosphate + UDP-glucose.
CC   -!- SUBUNIT: Homooctamer. {ECO:0000269|PubMed:22132858}.
CC   -!- INTERACTION:
CC       Self; NbExp=5; IntAct=EBI-743729, EBI-743729;
CC       O95376:ARIH2; NbExp=6; IntAct=EBI-743729, EBI-711158;
CC       O76003:GLRX3; NbExp=3; IntAct=EBI-743729, EBI-374781;
CC       P62993:GRB2; NbExp=2; IntAct=EBI-743729, EBI-401755;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:8354390}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q16851-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q16851-2; Sequence=VSP_012834;
CC         Note=Initiator Met-1 is removed. Contains a N-acetylserine at
CC         position 2. Contains a phosphoserine at position 2.
CC         {ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:21406692,
CC         ECO:0000244|PubMed:22223895, ECO:0000244|PubMed:22814378};
CC   -!- SIMILARITY: Belongs to the UDPGP type 1 family. {ECO:0000305}.
CC   -!- CAUTION: The human genome was initially thought to contain 2 genes
CC       for UTP--glucose-1-phosphate uridylyltransferase: UGP1 and UGP2.
CC       However, the sequence defined as UGP1 (PubMed:8354390) probably
CC       does not exist and corresponds to UGP2.
CC       {ECO:0000305|PubMed:8354390}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U27460; AAB05640.1; -; mRNA.
DR   EMBL; BC000173; AAH00173.2; -; mRNA.
DR   EMBL; BC002954; AAH02954.1; -; mRNA.
DR   EMBL; BC047004; AAH47004.1; -; mRNA.
DR   CCDS; CCDS1875.1; -. [Q16851-1]
DR   CCDS; CCDS42690.1; -. [Q16851-2]
DR   PIR; S35692; S35692.
DR   RefSeq; NP_001001521.1; NM_001001521.1. [Q16851-2]
DR   RefSeq; NP_006750.3; NM_006759.3. [Q16851-1]
DR   RefSeq; XP_005264594.1; XM_005264537.2. [Q16851-2]
DR   RefSeq; XP_005264595.1; XM_005264538.1. [Q16851-2]
DR   UniGene; Hs.516217; -.
DR   PDB; 3R2W; X-ray; 3.60 A; A/B/C/D=1-508.
DR   PDB; 3R3I; X-ray; 3.57 A; A/B/C/D=1-508.
DR   PDB; 4R7P; X-ray; 3.35 A; A/B/C/D=2-508.
DR   PDBsum; 3R2W; -.
DR   PDBsum; 3R3I; -.
DR   PDBsum; 4R7P; -.
DR   ProteinModelPortal; Q16851; -.
DR   SMR; Q16851; -.
DR   BioGrid; 113207; 54.
DR   IntAct; Q16851; 8.
DR   MINT; MINT-1468909; -.
DR   STRING; 9606.ENSP00000338703; -.
DR   iPTMnet; Q16851; -.
DR   PhosphoSitePlus; Q16851; -.
DR   SwissPalm; Q16851; -.
DR   BioMuta; UGP2; -.
DR   DMDM; 59803098; -.
DR   REPRODUCTION-2DPAGE; IPI00395676; -.
DR   UCD-2DPAGE; Q16851; -.
DR   EPD; Q16851; -.
DR   MaxQB; Q16851; -.
DR   PaxDb; Q16851; -.
DR   PeptideAtlas; Q16851; -.
DR   PRIDE; Q16851; -.
DR   DNASU; 7360; -.
DR   Ensembl; ENST00000337130; ENSP00000338703; ENSG00000169764. [Q16851-1]
DR   Ensembl; ENST00000394417; ENSP00000377939; ENSG00000169764. [Q16851-2]
DR   Ensembl; ENST00000467648; ENSP00000420793; ENSG00000169764. [Q16851-2]
DR   GeneID; 7360; -.
DR   KEGG; hsa:7360; -.
DR   UCSC; uc002scl.4; human. [Q16851-1]
DR   CTD; 7360; -.
DR   DisGeNET; 7360; -.
DR   GeneCards; UGP2; -.
DR   HGNC; HGNC:12527; UGP2.
DR   HPA; HPA034696; -.
DR   HPA; HPA034697; -.
DR   HPA; HPA064836; -.
DR   MIM; 191750; gene.
DR   MIM; 191760; gene.
DR   neXtProt; NX_Q16851; -.
DR   OpenTargets; ENSG00000169764; -.
DR   PharmGKB; PA37172; -.
DR   eggNOG; KOG2638; Eukaryota.
DR   eggNOG; COG4284; LUCA.
DR   GeneTree; ENSGT00390000003174; -.
DR   HOGENOM; HOG000113618; -.
DR   HOVERGEN; HBG055396; -.
DR   InParanoid; Q16851; -.
DR   KO; K00963; -.
DR   PhylomeDB; Q16851; -.
DR   TreeFam; TF300567; -.
DR   BioCyc; MetaCyc:HS10006-MONOMER; -.
DR   BRENDA; 2.7.7.9; 2681.
DR   Reactome; R-HSA-173599; Formation of the active cofactor, UDP-glucuronate.
DR   Reactome; R-HSA-3322077; Glycogen synthesis.
DR   SABIO-RK; Q16851; -.
DR   ChiTaRS; UGP2; human.
DR   GenomeRNAi; 7360; -.
DR   PRO; PR:Q16851; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000169764; -.
DR   CleanEx; HS_UGP2; -.
DR   ExpressionAtlas; Q16851; baseline and differential.
DR   Genevisible; Q16851; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005536; F:glucose binding; IEA:Ensembl.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0032557; F:pyrimidine ribonucleotide binding; IEA:Ensembl.
DR   GO; GO:0003983; F:UTP:glucose-1-phosphate uridylyltransferase activity; EXP:Reactome.
DR   GO; GO:0019255; P:glucose 1-phosphate metabolic process; IEA:Ensembl.
DR   GO; GO:0005978; P:glycogen biosynthetic process; TAS:Reactome.
DR   GO; GO:0005977; P:glycogen metabolic process; IBA:GO_Central.
DR   GO; GO:0006011; P:UDP-glucose metabolic process; IBA:GO_Central.
DR   GO; GO:0006065; P:UDP-glucuronate biosynthetic process; TAS:Reactome.
DR   CDD; cd00897; UGPase_euk; 1.
DR   Gene3D; 3.90.550.10; -; 1.
DR   InterPro; IPR029044; Nucleotide-diphossugar_trans.
DR   InterPro; IPR002618; UDPGP_fam.
DR   InterPro; IPR016267; UDPGP_trans.
DR   Pfam; PF01704; UDPGP; 1.
DR   PIRSF; PIRSF000806; UDPGP; 1.
DR   SUPFAM; SSF53448; SSF53448; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Cytoplasm; Magnesium; Metal-binding; Nucleotidyltransferase;
KW   Phosphoprotein; Polymorphism; Reference proteome; Transferase.
FT   CHAIN         1    508       UTP--glucose-1-phosphate
FT                                uridylyltransferase.
FT                                /FTId=PRO_0000185752.
FT   REGION      113    116       UTP binding.
FT                                {ECO:0000250|UniProtKB:Q9M9P3}.
FT   REGION      115    116       Substrate binding. {ECO:0000244|PDB:4R7P,
FT                                ECO:0000269|PubMed:25860585}.
FT   REGION      251    253       Substrate binding. {ECO:0000244|PDB:4R7P,
FT                                ECO:0000269|PubMed:25860585}.
FT   REGION      457    508       Oligomerization.
FT   REGION      502    503       Critical for end-to-end subunit
FT                                interaction.
FT   ACT_SITE    396    396       {ECO:0000250}.
FT   METAL       127    127       Magnesium. {ECO:0000250}.
FT   METAL       253    253       Magnesium. {ECO:0000250}.
FT   BINDING     127    127       UTP. {ECO:0000250|UniProtKB:Q9M9P3}.
FT   BINDING     190    190       UTP. {ECO:0000250|UniProtKB:Q9M9P3}.
FT   BINDING     222    222       UTP; via amide nitrogen.
FT                                {ECO:0000250|UniProtKB:Q9M9P3}.
FT   BINDING     223    223       Substrate. {ECO:0000244|PDB:4R7P,
FT                                ECO:0000269|PubMed:25860585}.
FT   BINDING     253    253       UTP. {ECO:0000250|UniProtKB:Q9M9P3}.
FT   BINDING     330    330       Substrate. {ECO:0000244|PDB:4R7P,
FT                                ECO:0000269|PubMed:25860585}.
FT   BINDING     396    396       UTP. {ECO:0000250|UniProtKB:Q9M9P3}.
FT   MOD_RES      13     13       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     426    426       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     434    434       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     438    438       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     448    448       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     461    461       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   VAR_SEQ       1     11       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:8631325}.
FT                                /FTId=VSP_012834.
FT   VARIANT     268    268       M -> I (in dbSNP:rs1130982).
FT                                {ECO:0000269|PubMed:8354390,
FT                                ECO:0000269|PubMed:8631325}.
FT                                /FTId=VAR_033042.
FT   MUTAGEN     123    123       C->S: No significant loss of activity.
FT                                {ECO:0000269|PubMed:8612650}.
FT   MUTAGEN     218    218       W->S: No significant loss of activity.
FT                                {ECO:0000269|PubMed:8612650}.
FT   MUTAGEN     266    266       H->R: No significant loss of activity.
FT                                {ECO:0000269|PubMed:8612650}.
FT   MUTAGEN     333    333       W->S: Loss of activity; possibly due to
FT                                folding defect.
FT                                {ECO:0000269|PubMed:8612650}.
FT   MUTAGEN     389    389       R->H: No significant loss of activity.
FT                                {ECO:0000269|PubMed:8612650}.
FT   MUTAGEN     391    391       R->H: Loss of activity; possibly due to
FT                                folding defect.
FT                                {ECO:0000269|PubMed:8612650}.
FT   MUTAGEN     422    422       R->H: No significant loss of activity.
FT                                {ECO:0000269|PubMed:8612650}.
FT   MUTAGEN     445    445       R->H: No significant loss of activity.
FT                                {ECO:0000269|PubMed:8612650}.
FT   MUTAGEN     502    503       NL->PE: Abolishes oligomerization and
FT                                significantly increases enzymatic
FT                                activity. {ECO:0000269|PubMed:22132858}.
FT   CONFLICT     25     25       R -> L (in Ref. 1). {ECO:0000305}.
FT   CONFLICT     44     44       S -> T (in Ref. 1). {ECO:0000305}.
FT   CONFLICT     48     48       F -> Y (in Ref. 1). {ECO:0000305}.
FT   CONFLICT     62     62       F -> Y (in Ref. 1). {ECO:0000305}.
FT   CONFLICT    152    152       T -> S (in Ref. 1). {ECO:0000305}.
FT   CONFLICT    202    202       L -> R (in Ref. 1 and 2; AAB05640).
FT                                {ECO:0000305}.
FT   CONFLICT    210    210       Y -> S (in Ref. 1). {ECO:0000305}.
FT   CONFLICT    214    214       N -> S (in Ref. 1). {ECO:0000305}.
FT   CONFLICT    240    241       IG -> LE (in Ref. 1). {ECO:0000305}.
FT   CONFLICT    356    356       A -> P (in Ref. 1). {ECO:0000305}.
FT   HELIX        25     41       {ECO:0000244|PDB:4R7P}.
FT   HELIX        45     47       {ECO:0000244|PDB:4R7P}.
FT   HELIX        49     65       {ECO:0000244|PDB:4R7P}.
FT   HELIX        75     77       {ECO:0000244|PDB:4R7P}.
FT   STRAND       85     88       {ECO:0000244|PDB:4R7P}.
FT   HELIX        89     95       {ECO:0000244|PDB:4R7P}.
FT   HELIX       101    105       {ECO:0000244|PDB:4R7P}.
FT   STRAND      108    114       {ECO:0000244|PDB:4R7P}.
FT   TURN        118    122       {ECO:0000244|PDB:4R7P}.
FT   STRAND      124    126       {ECO:0000244|PDB:4R7P}.
FT   HELIX       127    129       {ECO:0000244|PDB:4R7P}.
FT   STRAND      130    133       {ECO:0000244|PDB:4R7P}.
FT   HELIX       138    153       {ECO:0000244|PDB:4R7P}.
FT   STRAND      158    163       {ECO:0000244|PDB:4R7P}.
FT   TURN        165    167       {ECO:0000244|PDB:4R7P}.
FT   HELIX       168    172       {ECO:0000244|PDB:4R7P}.
FT   HELIX       173    178       {ECO:0000244|PDB:4R7P}.
FT   STRAND      179    182       {ECO:0000244|PDB:4R7P}.
FT   STRAND      184    189       {ECO:0000244|PDB:4R7P}.
FT   STRAND      196    200       {ECO:0000244|PDB:4R7P}.
FT   HELIX       210    212       {ECO:0000244|PDB:4R7P}.
FT   HELIX       215    217       {ECO:0000244|PDB:4R7P}.
FT   HELIX       226    232       {ECO:0000244|PDB:4R7P}.
FT   HELIX       235    241       {ECO:0000244|PDB:4R7P}.
FT   STRAND      246    254       {ECO:0000244|PDB:4R7P}.
FT   HELIX       261    268       {ECO:0000244|PDB:4R7P}.
FT   HELIX       271    273       {ECO:0000244|PDB:4R7P}.
FT   STRAND      277    284       {ECO:0000244|PDB:4R7P}.
FT   STRAND      294    298       {ECO:0000244|PDB:4R7P}.
FT   STRAND      301    305       {ECO:0000244|PDB:4R7P}.
FT   HELIX       307    309       {ECO:0000244|PDB:4R7P}.
FT   HELIX       315    319       {ECO:0000244|PDB:4R7P}.
FT   TURN        321    323       {ECO:0000244|PDB:4R7P}.
FT   STRAND      326    335       {ECO:0000244|PDB:4R7P}.
FT   HELIX       336    344       {ECO:0000244|PDB:4R7P}.
FT   STRAND      353    359       {ECO:0000244|PDB:4R7P}.
FT   TURN        360    362       {ECO:0000244|PDB:4R7P}.
FT   STRAND      363    369       {ECO:0000244|PDB:4R7P}.
FT   HELIX       372    378       {ECO:0000244|PDB:4R7P}.
FT   STRAND      383    386       {ECO:0000244|PDB:4R7P}.
FT   HELIX       389    391       {ECO:0000244|PDB:4R7P}.
FT   HELIX       398    405       {ECO:0000244|PDB:4R7P}.
FT   STRAND      409    412       {ECO:0000244|PDB:4R7P}.
FT   STRAND      415    418       {ECO:0000244|PDB:4R7P}.
FT   STRAND      423    426       {ECO:0000244|PDB:4R7P}.
FT   STRAND      429    432       {ECO:0000244|PDB:4R7P}.
FT   HELIX       434    436       {ECO:0000244|PDB:4R7P}.
FT   HELIX       439    445       {ECO:0000244|PDB:4R7P}.
FT   STRAND      446    448       {ECO:0000244|PDB:4R7P}.
FT   STRAND      455    460       {ECO:0000244|PDB:4R7P}.
FT   STRAND      462    466       {ECO:0000244|PDB:4R7P}.
FT   STRAND      471    480       {ECO:0000244|PDB:4R7P}.
FT   STRAND      485    488       {ECO:0000244|PDB:4R7P}.
FT   STRAND      493    496       {ECO:0000244|PDB:4R7P}.
FT   STRAND      498    501       {ECO:0000244|PDB:4R7P}.
SQ   SEQUENCE   508 AA;  56940 MW;  60E54806807AB470 CRC64;
     MSRFVQDLSK AMSQDGASQF QEVIRQELEL SVKKELEKIL TTASSHEFEH TKKDLDGFRK
     LFHRFLQEKG PSVDWGKIQR PPEDSIQPYE KIKARGLPDN ISSVLNKLVV VKLNGGLGTS
     MGCKGPKSLI GVRNENTFLD LTVQQIEHLN KTYNTDVPLV LMNSFNTDED TKKILQKYNH
     CRVKIYTFNQ SRYPRINKES LLPVAKDVSY SGENTEAWYP PGHGDIYASF YNSGLLDTFI
     GEGKEYIFVS NIDNLGATVD LYILNHLMNP PNGKRCEFVM EVTNKTRADV KGGTLTQYEG
     KLRLVEIAQV PKAHVDEFKS VSKFKIFNTN NLWISLAAVK RLQEQNAIDM EIIVNAKTLD
     GGLNVIQLET AVGAAIKSFE NSLGINVPRS RFLPVKTTSD LLLVMSNLYS LNAGSLTMSE
     KREFPTVPLV KLGSSFTKVQ DYLRRFESIP DMLELDHLTV SGDVTFGKNV SLKGTVIIIA
     NHGDRIDIPP GAVLENKIVS GNLRILDH
//
